Targeting epigenetic regulators to boost T cell immunotherapy against cancer.

Abstract readReview

In one paragraph

Review in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tiaojiang XiaoLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Building 37, RM 2056, Bethesda, MD, 20892-4256, USA. tiaojiang.xiao@nih.gov.ORCID http://orcid.org/0000-0002-2794-3944

Ying E ZhangLaboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Building 37, RM 2056, Bethesda, MD, 20892-4256, USA.ORCID http://orcid.org/0000-0003-2753-7601

Funding

Molecular Mechanisms of TGF-beta Signaling PathwayZIABC010419 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ZHANG, YING E · 2009 to 2025

$14.9M

NCI NIH HHS ZIA BC 010419

6 · The paper itself

Abstract

Epigenetic regulation is crucial in directing T-cell differentiation, function, and fate, thereby influencing the success of T-cell-based immunotherapies. This review begins with an overview of the evolution of T-cell immunotherapies in cancer treatment. We then examine key epigenetic regulators-such as DNA methylation, mRNA methylation, and histone methylation-and their roles in shaping T-cell states during infection and tumorigenesis. The contributions of these regulators to T-cell exhaustion and lineage commitment are discussed in the context of immunotherapy efficacy. We highlight recent advances in targeting epigenetic pathways to enhance CAR-T and TCR-based therapies and conclude with current challenges and emerging strategies to improve the durability and effectiveness of adoptive T-cell therapies.

Indexed as

Chromatin modificationEpigenetic regulatorT-cell based immunotherapyTumor microenvironment (TME)

Identifiers

PMID41634788

DOI10.1186/s13578-026-01533-y

PMCPMC12958680

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.